Kiora Pharmaceuticals (KPRX) Receivables Refunds (2016 - 2025)
Kiora Pharmaceuticals (KPRX) has disclosed Receivables Refunds for 11 consecutive years, with $722290.0 as the latest value for Q1 2025.
- For the quarter ending Q1 2025, Receivables Refunds fell 60.07% year-over-year to $722290.0, compared with a TTM value of $722290.0 through Mar 2025, down 60.07%, and an annual FY2024 reading of $270246.0, down 86.82% over the prior year.
- Receivables Refunds was $722290.0 for Q1 2025 at Kiora Pharmaceuticals, up from $270246.0 in the prior quarter.
- Across five years, Receivables Refunds topped out at $2.0 million in Q4 2023 and bottomed at $147104.0 in Q1 2021.
- Average Receivables Refunds over 5 years is $876174.3, with a median of $552951.0 recorded in 2022.
- The sharpest move saw Receivables Refunds surged 20357.99% in 2021, then tumbled 86.82% in 2024.
- Year by year, Receivables Refunds stood at $529560.0 in 2021, then soared by 195.07% to $1.6 million in 2022, then skyrocketed by 31.19% to $2.0 million in 2023, then tumbled by 86.82% to $270246.0 in 2024, then soared by 167.27% to $722290.0 in 2025.
- Business Quant data shows Receivables Refunds for KPRX at $722290.0 in Q1 2025, $270246.0 in Q4 2024, and $363706.0 in Q3 2024.